Patel Nilay S, Dobbie Michael S, Rochester Mark, Steers Graham, Poulsom Richard, Le Monnier Karena, Cranston David W, Li Ji-Liang, Harris Adrian L
Growth Factor Group, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom.
Clin Cancer Res. 2006 Aug 15;12(16):4836-44. doi: 10.1158/1078-0432.CCR-06-0285.
Angiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about the mechanisms, we studied the role of delta-like 4 (DLL4), an endothelial-specific ligand of the Notch signaling pathway, in bladder cancer angiogenesis.
The expression of DLL4, CD34, and VEGF were studied in a cohort of 60 bladder tumors and 10 normal samples using quantitative PCR. In situ hybridization was used to study the pattern of DLL4 expression in 22 tumor and 9 normal samples. Serial sections were also stained for CD34 and alpha-smooth muscle actin (alpha-SMA) using conventional immunohistochemistry.
The expression of DLL4 was significantly up-regulated in superficial (P < 0.01) and invasive (P < 0.05) bladder cancers. DLL4 expression significantly correlated with CD34 (P < 0.001) and VEGF (P < 0.001) expression. The in situ hybridization studies showed that DLL4 was highly expressed within bladder tumor vasculature. Additionally, DLL4 expression significantly correlated with vessel maturation as judged by periendothelial cell expression of alpha-SMA, 98.7% of DLL4-positive tumor vessels coexpressed alpha-SMA, compared with 64.5% of DLL4-negative tumor vessels (P < 0.001). High DLL4 expression may have prognostic value in superficial and invasive bladder.
DLL4 expression is associated with vascular differentiation in bladder cancer; thus, targeting DLL4 may be a novel antiangiogenic therapy.
血管生成和血管内皮生长因子(VEGF)表达与膀胱癌的不良预后相关。为了更深入了解其机制,我们研究了Notch信号通路的内皮特异性配体Delta样蛋白4(DLL4)在膀胱癌血管生成中的作用。
使用定量PCR研究了60例膀胱肿瘤和10例正常样本中DLL4、CD34和VEGF的表达。采用原位杂交研究22例肿瘤和9例正常样本中DLL4的表达模式。连续切片还使用传统免疫组织化学方法对CD34和α-平滑肌肌动蛋白(α-SMA)进行染色。
DLL4在浅表性膀胱癌(P < 0.01)和浸润性膀胱癌(P < 0.05)中的表达显著上调。DLL4表达与CD34(P < 0.001)和VEGF(P < 0.001)表达显著相关。原位杂交研究表明,DLL4在膀胱肿瘤血管中高表达。此外,根据α-SMA的周内皮细胞表达判断,DLL4表达与血管成熟显著相关,98.7%的DLL4阳性肿瘤血管共表达α-SMA,而DLL4阴性肿瘤血管的这一比例为64.5%(P < 0.001)。高DLL4表达可能对浅表性和浸润性膀胱癌具有预后价值。
DLL4表达与膀胱癌的血管分化相关;因此,靶向DLL4可能是一种新型抗血管生成疗法。